References
- Horiguchi S, Saito Y. Japanese cedar pollinosis in Nikko, Japan. Jpn J Allergol 1964;13:16-18 (in Japanese with English abstract)
- Okuda M. Epidemiology of Japanese cedar pollinosis throughout Japan. Ann Allergy Asthma Immunol 2003;91:288-96
- Sakashita M, Hirota T, Harada M, et al. Prevalence of allergic rhinitis and sensitization to common aeroallergens in a Japanese population. Int Arch Allergy Immunol 2010;151:255-61
- Okubo K, Kurono Y, Fujieda S, et al. Japanese guideline for allergic rhinitis. Allergol Int 2011;60:171-89
- Asher MI, Keil U, Anderson HR, et al. International study of asthma and allergies in childhood (ISAAC): rationale and methods. Eur Respir J 1995;8:483-91
- The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Worldwide variation in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis and atopic eczema: ISAAC. Lancet 1998;351:1225–32
- Okubo K, Gotoh M, Shimada K, et al. Fexofenadine improves the quality of life and work productivity in Japanese patients with seasonal allergic rhinitis during the peak cedar pollinosis season. Int Arch Allergy Immunol 2005;136:148-54
- Mizutani N, Nabe T, Imai A, et al. Markedly increased nasal blockage by intranasal leukotriene D4 in an experimental allergic rhinitis model: contribution of dilated mucosal blood vessels. Jpn J Pharmacol 2001;86:170-82
- Shirasaki H, Kojima T, Asakura K, et al. The pathophysiological role of kinin and chemical mediators on experimental allergic rhinitis. Adv Exp Med Biol 1989;247A:375-8
- Oshima N, Nagase H, Koshino T, et al. A functional study on CysLT(1) receptors in human eosinophils. Int Arch Allergy Immunol 2002;129:67-75
- Thivierge M, Stankova J, Rola-Plerszczynski M. IL-13 and IL-4 up-regulate cysteinyl leukotriene 1 receptor expression in human monocytes and macrophages. J Immunol 2001;167:2855-60
- Peters-Golden M, Gleason MM, Togias A. Cysteinyl leukotriene: multi-functional mediators in allergic rhinitis. Clin Exp Allergy 2006;36:689-703
- Fujita M, Yonetomi Y, Takeda H, et al. Effects of specific cysteinyl leukotriene antagonist, pranlukast, on antigen-induced cysteinyl leukotriene-mediated rhinitis in guinea pigs. Jpn J Pharmacol 1997;75:347-53
- Lipworth BJ. Emerging role of antileukotriene therapy in allergic rhinitis. Clin Exp allergy 2001;31:1813-21
- Meltzer EO. Clinical evidence for antileukotriene therapy in the management of allergic rhinitis. Ann Allergy Asthma Immunol 2002;88(4 Suppl 1):23-9
- Philip G, Malmstrom K, Hampel FC, et al. Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring. Clin Exp Allergy 2002;32:1020-8
- Van Adelsberg J, Philip G, Pedinoff AJ, et al. Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period. Allergy 2003;58:1268-76
- Meltzer EO, Philip G, Weinstein SF, et al. Montelukast effectively treats the nighttime impact of seasonal allergic rhinitis. Am J Rhinol 2005;19:591-8
- Kurowski M, Kuna P, Gorski P. Montelukast plus cetirizine in the prophylactic treatment of seasonal allergic rhinitis: influence on clinical symptoms and nasal allergic inflammation. Allergy 2004;59:280-8
- Sasaki K, Okamoto Y, Yonekura S, et al. Cedar and cypress pollinosis and allergic rhinitis: quality of life effects of early intervention with leukotriene receptor antagonists. Int Arch Allergy Immunol 2009;149:350-8
- Yonekura S, Okamoto Y, Okubo K, et al. Beneficial effects of leukotriene receptor antagonists in the prevention of cedar pollinosis in a community setting. J Investig Allergol Clin Immunol 2009;19:195-203
- Gotoh M, Suzuki H, Okubo K. Delay of onset of symptoms of Japanese cedar pollinosis by treatment with a leukotriene receptor antagonist. Allergol Int 2011;60:483-9
- Ueda T, Takeno S, Furukido K, et al. Leukotriene receptor antagonist pranlukast suppresses eosinophil infiltration and cytokine production in human nasal mucosa of perennial allergic rhinitis. Ann Otol Rhinol Laryngol 2003;112:955-61
- Endo S, Gotoh M, Okubo K, et al. Trial of pranlukast inhibitory effect for cedar exposure using an OHIO chamber. J Drug Assess 2012;1:48-54
- Okubo K, Hashiguchi K, Masuno S. Protective effect of pranlukast hydrate against the priming states of Japanese cedar pollen and the large of pollen-exposure. 17th Congress of the APSR (Asian Pacific Society of Respirology), Hong Kong, 2012
- Wakabayashi K, Hashiguchi K, Kanzaki S, et al. Pranlukast dry syrup inhibits symptoms of Japanese cedar pollinosis in children using OHIO Chamber. Allergy Asthma Proc 2012;33:102-9
- Gotoh M, Okubo K, Hashiguchi K, et al. Noninvasive biological evaluation of response to pranlukast treatment in pediatric patients with Japanese cedar pollinosis. Allergy Asthma Proc 2012;33:459-66
- Hashiguchi K, Tang H, Fujita T, et al. Preliminary study on Japanese cedar pollinosis in an artificial exposure chamber (OHIO Chamber). Allergol Int 2007;56:125-30
- Hashiguchi K, Tang H, Fujita T, et al. Pilot study of Japanese cedar pollen exposure using a novel artificial exposure chamber (OHIO Chamber). Clin Exp Allergy Rev 2008;8:30-6
- Hashiguchi K, Tang H, Fujita T, et al. Validation study of the OHIO Chamber in patients with Japanese cedar pollinosis. Int Arch Allergy Immunol 2009;149:141-9
- Storms WW. Minimal persistent inflammation, an emerging concept in the nature and treatment of allergic rhinitis: the possible role of leukotrienes. Ann Allergy Asthma Immunol 2003;91:131-40
- Canonica GW, Compalati E. Minimal persistent inflammation in allergic rhinitis: implications for current treatment strategies. Clin Exp Immunol 2009;158:260-71
- Roquat A, Ihre E, van Hage-Hamsten M, et al. Allergen-induced inflammation in the nose: a comparison of acute and repeated low-dose allergen exposure. Allergy 1996;51:42-8
- Bachert C, van Kempen M, van Cauwenberge P. Regulation of proinflammatory cytokines in seasonal allergic rhinitis. Int Arch Allergy Immunol 1999;118:375-9